Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder

World Journal of Biological Psychiatry

Volumn 6, Issue 1, 2005, Pages 57-59

  Fontenelle, Leonardo F ^a,d   Mendlowicz, Mauro V ^a,c   Miguel, Euripedes C ^b   Versiani, Marcio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d NONE   (Brazil)

Author keywords

Citalopram; Obsessive compulsive disorder; Reboxetine

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CASE REPORT; CONTAMINATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; FEAR; FUNCTIONAL ASSESSMENT; HAMILTON SCALE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; RATING SCALE; SCORING SYSTEM; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHRONIC DISEASE; CITALOPRAM; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MORPHOLINES; OBSESSIVE-COMPULSIVE DISORDER; RECURRENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 19444382365     PISSN: 15622975     EISSN: None     Source Type: Journal    
DOI: 10.1080/15622970510029740     Document Type: Article

References (22)

1. Ackerman DL, Greenland S. 2002. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 22:309-317.
2. Albert U, Aguglia E, Maina G, Bogetto F. 2002. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: A preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 63:1004-1009.
3. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. 1997. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 154:1293-1295.
4. Benfield DP, Harries CM, Luscombe DK. 1980. Some pharmacological aspects of desmethylclomipramine. Postgrad Med J 56(Suppl 1):13-18.
5. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. 2004. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. J Clin Psychiatry 65:565-568.
6. Denys D, van der Wee N, van Megen HJ, Westenberg HG. 2003. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 23: 568-575.
7. Denys D, van Megen HJ, van der Wee N, Westenberg HG. 2004a. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65:37-43.
8. Denys D, de Geus F, van Megen HJ, Westenberg HG. 2004b. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
9. Devarajan S, Dursun SM. 2000. Citalopram plus reboxetine in treatment-resistant depression. Can J Psychiatry 45:489-490.
10. Dursun SM, Devarajan S. 2001. Reboxetine plus citalopram for refractory depression not responding to venlafaxine: Possible mechanisms. Psychopharmacology (Berlin) 153:497-498.
11. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. 1995. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 52:53-60.
12. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. 2002. Refractory obsessive-compulsive disorder: State-of-the-art treatment. J Clin Psychiatry 63 (Suppl 6):20-29.
13. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. 2003. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 64:546-550.
14. Mancini C, Van Ameringen M, Farvolden P. 2002. Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder? J Affect Disord 68:59-65.
15. Marazziti D. 2003. Venlafaxine treatment of obsessive-compulsive disorder: Case reports. CNS Spectr 8:421-422.
16. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. 1994. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
17. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. 2000. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801.
18. Noorbala AA, Hosseini SH, Mohammadi MR, Akhondzadeh S. 1998. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. J Clin Pharm Ther 23:155-159.
19. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. 1995. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 166:424-443.
20. Stein DJ, Spadaccini E, Hollander E. 1995. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10:11-18.
21. Walsh KH, McDougle CJ. 2004. Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opin Pharmacother 5:2059-2067.
22. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA. 2000. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47:818-829.